30-Apr-2024
Glaukos Q1 2024 Earnings Preview
Seeking Alpha News (Tue, 30-Apr 5:35 PM ET)
Glaukos Announces the Release of its 2023 Sustainability Report
Business Wire (Tue, 16-Apr 4:05 PM ET)
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
Business Wire (Wed, 10-Apr 7:00 AM ET)
Glaukos Receives Permanent J-code for iDose TR (travoprost intracameral implant)
Business Wire (Wed, 3-Apr 7:00 AM ET)
Business Wire (Mon, 1-Apr 7:00 AM ET)
Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
Business Wire (Wed, 21-Feb 4:05 PM ET)
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Glaukos trades on the NYSE stock market under the symbol GKOS.
As of April 30, 2024, GKOS stock price declined to $96.00 with 396,167 million shares trading.
GKOS has a beta of 0.78, meaning it tends to be less sensitive to market movements. GKOS has a correlation of 0.05 to the broad based SPY ETF.
GKOS has a market cap of $4.82 billion. This is considered a Mid Cap stock.
Last quarter Glaukos reported $82 million in Revenue and -$.63 earnings per share. This beat revenue expectation by $4 million and missed earnings estimates by -$.08.
In the last 3 years, GKOS stock traded as high as $103.66 and as low as $33.33.
The top ETF exchange traded funds that GKOS belongs to (by Net Assets): IJR, VTI, VB, IWM, VXF.
GKOS has outperformed the market in the last year with a return of +102.1%, while the SPY ETF gained +22.3%. In the last 3 month period, GKOS beat the market returning +5.4%, while SPY returned +2.6%. However, in the most recent 2 weeks GKOS has underperformed the stock market by returning -1.0%, while SPY returned -0.3%.
GKOS support price is $94.78 and resistance is $99.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GKOS stock will trade within this expected range on the day.